Crown Advisors Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Crown Advisors Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,500	Closed	-$568K	–	47
2023 Q2	$568K	Hold	1,500	–	–	0.37%	51
2023 Q1	$718K	Hold	1,500	–	–	0.54%	44
2022 Q4	$630K	Hold	1,500	–	–	0.57%	41
2022 Q3	$625K	Hold	1,500	–	–	0.62%	40
2022 Q2	$742K	Hold	1,500	–	–	0.68%	41
2022 Q1	$844K	Hold	1,500	–	–	0.59%	43
2021 Q4	$1.13M	Hold	1,500	–	–	0.73%	37
2021 Q3	$1.12M	Hold	1,500	–	–	0.79%	37
2021 Q2	$966K	Hold	1,500	–	–	0.67%	38
2021 Q1	$857K	Hold	1,500	–	–	0.67%	37
2020 Q4	$874K	Hold	1,500	–	–	0.63%	35
2020 Q3	$773K	Hold	1,500	–	–	0.5%	41
2020 Q2	$677K	Hold	1,500	–	–	0.46%	41
2020 Q1	$526K	Buy	+1,500	New	+$552K	0.42%	40

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.56B AUM 3.46% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $64.6B AUM 18.98% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

UBS AM Chicago, Illinois $550B AUM 43.33% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Crown Advisors Management's BIO Position: Q3 2023 in Review

Crown Advisors Management sold out of Bio-Rad Laboratories Class A (BIO) in Q3 2023, closing a stake of 1,500 shares — an estimated $568K sold.

Crown Advisors Management first reported a position in BIO in Q1 2020 and held it in 14 quarters. The position peaked at $1.13M in Q4 2021. 468 funds tracked by Wall St. Rank hold BIO as of Q3 2023.

Crown Advisors Management reported no remaining Bio-Rad Laboratories Class A position as of Q3 2023 after selling out during the quarter.
Crown Advisors Management sold 1,500 Bio-Rad Laboratories Class A shares in Q3 2023, an estimated $568K.
Crown Advisors Management first reported a position in Bio-Rad Laboratories Class A in Q1 2020 and held it in 14 quarters.
Crown Advisors Management's Bio-Rad Laboratories Class A position peaked at $1.13M in Q4 2021.
468 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2023.

Based on Crown Advisors Management's 13F filing for Q3 2023, filed 9 Nov 2023.